Finance

Lists
IDYA:NASDAQ
Ideaya Biosciences Inc
$38.35
-0.67%
(-0.26) 1D
Sep 18, 12:52:17 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IDYA...
Open
$38.88
High
$39.24
Low
$38.15
Mkt. cap
3.71B
Avg. vol.
672.58K
Volume
216.18K
52-wk high
$42.68
52-wk low
$25.27
EPS
-$1.94
Beta
-0.07
Shares outstanding
96.49M
No. of employees
145
Open
$38.88
High
$39.24
Low
$38.15
Mkt. cap
3.71B
Avg. vol.
672.58K
Volume
216.18K
52-wk high
$42.68
52-wk low
$25.27
EPS
-$1.94
Beta
-0.07
Shares outstanding
96.49M
No. of employees
145
News stories
From web sources and news partners
About Ideaya Biosciences Inc
CEO-
Employees145
Founded2015
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteideayabio.com
Analyst ratings
Based on 10 analysts giving stock ratings to IDYA in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for IDYA in the last 3 months.
Highest
Current $38.35
$65.00 (+69.49%)
Average
$54.44 (+41.96%)
Lowest
$42.00 (+9.52%)
Analyst
Recommendation
Action
Price target
Projected
Date
Charles Zhu
LifeSci Capital
Buy
Maintained
$58.00
+51.2%
09/18/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$65.00
+69.5%
09/10/2026
Paul Jeng
Guggenheim
Buy
Maintained
$57.00
+48.6%
09/09/2026
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$50.00
+30.4%
09/01/2026
Gregory Renza
Truist Financial
Buy
Maintained
-
-
09/01/2026
Robert Driscoll
Wedbush
Buy
Maintained
$60.00
+56.5%
08/20/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$62.00
+61.7%
08/10/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
$42.00
+9.5%
08/06/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Maintained
$48.00
+25.2%
08/05/2026
Leonid Timashev
RBC Capital
Buy
Maintained
$48.00
+25.2%
08/04/2026
Michael Yee
UBS
Buy
Reiterated
$50.00
+30.4%
06/09/2026
Corinne Johnson
Goldman Sachs
Hold
Maintained
$36.00
-6.1%
06/03/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/05/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
$35.00
-8.7%
04/14/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$48.00
+25.2%
04/14/2026
Maury Raycroft
Jefferies
Buy
Maintained
$52.00
+35.6%
04/05/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$1.22 / -$1.05
-16.17%miss
Revenue / Est. (USD)
8.86M / 7.45M
+18.94%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
207.83M
10.88M
6.56M
8.86M
Cost of goods sold
82.99M
86.60M
95.73M
108.69M
Cost of revenue
82.99M
86.60M
95.73M
108.69M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
16.39M
18.85M
19.38M
22.46M
Operating expense
16.39M
18.85M
19.38M
22.46M
Total operating expenses
99.38M
105.45M
115.10M
131.15M
Operating income
108.45M
-94.57M
-108.54M
-122.29M
Other non operating income
-
-
-
-
EBT including unusual items
119.24M
-83.27M
-98.54M
-112.45M
EBT excluding unusual items
119.24M
-93.25M
-98.54M
-112.45M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
119.24M
-83.27M
-98.54M
-112.45M
Net profit margin
57.37%
-765.66%
-1,502.12%
-1,269.64%
Earnings per share
1.33
-0.94
-1.11
-1.22
Interest and investment income
10.79M
1.32M
10.00M
9.84M
Interest expense
-
-
-
-
Net interest expenses
10.79M
1.32M
10.00M
9.84M
Depreciation and amortization charges
-
-
-
-
EBITDA
109.11M
-93.85M
-107.86M
-121.60M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps